B. Michael Longenecker
15Patents
5h-index
7Co-inventors
59Inventor score
Filing activity: Jul 21, 1988 → Sep 17, 2014
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5110911A | Human tumor-associated Thomsen-Friedenreich antigen | Emerging Cross-Sectional Technologies | 52 | Expired |
| US6600012B1 | Lipid-modified muc-1 derivatives | Emerging Cross-Sectional Technologies | 26 | Expired |
| US5242799A | Lectin-antibody immunoassays for TF epitope-bearing antigens | Emerging Cross-Sectional Technologies | 10 | Expired |
| US5798090A | Enhancement of the cellular immune response | Human Necessities | 8 | Expired |
| USRE38046E1 | Enhancement of the cellular immune response | General | 7 | Expired |
| US4971795A | Enhancement of the cellular immune response using carbohydrate primed DTH effector cells expressing the CD5+/CD8- phenotype | Human Necessities | 5 | Expired |
| US6602660B1 | Methods of detecting T-cell activation | Physics | 3 | Expired |
| US6114129A | Methods of detecting T-cell activation and treating disorders associated with T-cell dysfunction | Physics | 3 | Expired |
| US8198400B2 | Vaccine for modulating between T1 and T2 immune responses | Emerging Cross-Sectional Technologies | 2 | Expired |
| US8552145B2 | Vaccine for modulating between T1 and T2 immune responses | Emerging Cross-Sectional Technologies | 1 | Active |
| US8871250B2 | Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine | Physics | 1 | Active |
| US9119784B2 | Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine | Physics | 0 | Active |
| US6582697B2 | Enhancement of the cellular immune response | Human Necessities | 0 | Expired |
| US9173929B2 | Mucinous glycoprotein (MUC-1) vaccine | Human Necessities | 0 | Active |
| US6326009A | Enhancement of the cellular immune response | Human Necessities | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.